B+
Bull case
25%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-05-15 · RankAlpha Sentiment Codex
AVIR
AteaCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-05-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.20
Analysis reference price unavailable
Analysis 2026-05-15 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-15
Recent news sentiment (30D)
+50.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+57.2
Score
AI commentary
This T+3 earnings follow-up still reads as a monitoring setup rather than a thesis upgrade. The May 12 company source reaffirmed trial timing and runway but did not provide new clinical data, and checked evidence did not surface a clear delayed analyst target or estimate revision after the print. Secondary coverage described the immediate market reaction as subdued, and the packet's May 14 anchor close was $4.27, suggesting investors are waiting for the mid-2026 C-BEYOND readout instead of rewarding the quarter itself. Peer context remains tentative because the most relevant operating benchmarks are large HCV incumbents, not close small-cap biotech peers.
RankAlpha Sentiment Codex - 2026-05-15
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-07-01eventC-BEYOND Phase 3 topline remains the key mid-2026 inflectionHigh impact
In its May 12 earnings update, Atea reaffirmed that C-BEYOND in North America was fully enrolled in December 2025 with more than 880 patients and that topline results are still expected in mid-2026, leaving the stock largely tethered to a single near-term binary readout [#8-K-2026-05-12] [#10-Q-2026-05-12].
2026-07-01eventAT-587 Phase 1 start could add a second clinical program in mid-2026High impact
Atea said AT-587 was selected as the lead HEV candidate and that first-in-human Phase 1 initiation is expected in mid-2026, which could modestly broaden the narrative beyond HCV but remains early-stage relative to the Phase 3 value driver [#8-K-2026-05-12] [#10-Q-2026-05-12].
2026-12-31catalystC-FORWARD and March 2027 NDA path extend the HCV thesis beyond the first readoutHigh impact
The Q1 filing says C-FORWARD enrollment is expected to complete in mid-2026 with topline results around year-end 2026, and management is targeting a March 2027 NDA submission if Phase 3 results are successful, which supports a multi-step HCV timeline rather than a one-event story [#10-Q-2026-05-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-15 • Updated nightlySource: Internal modelMethodology